Role of TNF in mediating renal insufficiency following cardiac surgery: Evidence of a postbypass cardiorenal syndrome

被引:84
作者
Meldrum, DR
Donnahoo, KK
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Surg, Denver, CO 80262 USA
[2] Indiana Univ, Med Ctr, Dept Urol, Indianapolis, IN 46202 USA
关键词
cardiopulmonary bypass; ATN; ischemia and reperfusion injury; p38; MAPK; adenosine; TNF-binding protein; antioxidant; NF kappa B; gp130; preconditioning; heat shock; heart; cytokines;
D O I
10.1006/jsre.1999.5660
中图分类号
R61 [外科手术学];
学科分类号
摘要
Recent evidence has implicated proinflammatory mediators such as TNF-alpha in the pathophysiology of ischemia-reperfusion (I/R) injury. Clinically, serum levels of TNF-alpha are increased after myocardial infarction and after cardiopulmonary bypass. Both cardiopulmonary bypass and renal ischemia-reperfusion injury induce a cascade of events leading to cellular damage and organ dysfunction. Tumor necrosis factor (TNF), a potent proinflammatory cytokine, is released from both the heart and the kidney in response to ischemia and reperfusion. TNF released during cardiopulmonary bypass induces glomerular fibrin deposition, cellular infiltration, and vasoconstriction, leading to a reduction in glomerular filtration rate (GFR). The signaling cascade through which renal ischemia-reperfusion induces TNF production is beginning to be elucidated. Oxidants released following reperfusion activate p38 mitogen-activated protein kinase (p38 MAP kinase) and the TNF transcription factor, NF kappa B, leading to subsequent TNF synthesis. In a positive feedback, proinflammatory fashion, binding of TNF to specific TNF membrane receptors can reactivate NF kappa B. This provides a mechanism by which TNF can upregulate its own expression as well as facilitate the expression of other genes pivotal to the inflammatory response. Following its production and release, TNF results in both renal and myocardial apoptosis and dysfunction. An understanding of these mechanisms may allow the adjuvant use of anti-TNF therapeutic strategies in the treatment of renal injury. The purposes of this review are: (1) to evaluate the evidence which indicates that TNF is produced by the heart following cardiopulmonary bypass; (2) to examine the effect of TNF on myocardial performance; (3) to outline the mechanisms by which the kidney produces significant TNF in response to ischemia and reperfusion; (5) to investigate the role of TNF in renal ischemia-reperfusion injury, (6) to describe the mechanisms of TNF-induced renal cell apoptosis, and (7) to suggest potential anti-TNF strategies designed to reduce renal insufficiency following cardiac surgery. (C) 1999 Academic Press.
引用
收藏
页码:185 / 199
页数:15
相关论文
共 206 条
[31]   ERYTHROCYTES DECREASE MYOCARDIAL HYDROGEN-PEROXIDE LEVELS AND REPERFUSION INJURY [J].
BROWN, JM ;
GROSSO, MA ;
TERADA, LS ;
BEEHLER, CJ ;
TOTH, KM ;
WHITMAN, GJ ;
HARKEN, AH ;
REPINE, JE .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (02) :H584-H588
[32]   ENDOTOXIN PRETREATMENT INCREASES ENDOGENOUS MYOCARDIAL CATALASE ACTIVITY AND DECREASES ISCHEMIA REPERFUSION INJURY OF ISOLATED RAT HEARTS [J].
BROWN, JM ;
GROSSO, MA ;
TERADA, LS ;
WHITMAN, GJR ;
BANERJEE, A ;
WHITE, CW ;
HARKEN, AH ;
REPINE, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (07) :2516-2520
[33]   XANTHINE-OXIDASE PRODUCES HYDROGEN-PEROXIDE WHICH CONTRIBUTES TO REPERFUSION INJURY OF ISCHEMIC, ISOLATED, PERFUSED RAT HEARTS [J].
BROWN, JM ;
TERADA, LS ;
GROSSO, MA ;
WHITMANN, GJ ;
VELASCO, SE ;
PATT, A ;
HARKEN, AH ;
REPINE, JE .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (04) :1297-1301
[34]  
BULLOUGH DA, 1995, J IMMUNOL, V155, P2579
[35]  
BUSCHER D, 1995, MOL CELL BIOL, V15, P466
[36]  
BUTT TR, 1995, GENE EXPRESSION, V4, P319
[37]  
CAIN BS, 1999, IN PRESS CRIT CARE M
[38]  
CAIN BS, 1998, IN PRESS J MOL CELL
[39]  
Cameron D, 1996, J CARDIOVASC PHARM, V27, pS1
[40]   TUMOR-NECROSIS-FACTOR INDUCES CONTRACTION OF MESANGIAL CELLS AND ALTERS THEIR CYTOSKELETONS [J].
CAMUSSI, G ;
TURELLO, E ;
TETTA, C ;
BUSSOLINO, F ;
BAGLIONI, C .
KIDNEY INTERNATIONAL, 1990, 38 (05) :795-802